What question did this study set out to answer?

To compare treatment switching rates and therapy sequencing among zanubrutinib, acalabrutinib, and ibrutinib in CLL and SLL.

February 12, 2026Expert Review of Hematology

Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma

View Full Paper

Ask AI

Bookmark

To compare treatment switching rates and therapy sequencing among zanubrutinib, acalabrutinib, and ibrutinib in CLL and SLL.
Analyzed treatment data for zanubrutinib, acalabrutinib, and ibrutinib.
Compared 90-day switching rates between treatments.
Assessed proportion of patients on the next line of therapy at 180 days.
Zanubrutinib showed lower 90-day switching rates compared to acalabrutinib and ibrutinib.
A higher proportion of patients receiving zanubrutinib were on the next line of therapy at 180 days.

Implication

Real-world treatment switching impacts next line therapy in chronic lymphocytic leukemia and small lymphocytic lymphoma, suggesting differences in efficacy among treatments.

Abstract

Zanubrutinib was associated with lower 90-day switching rates and estimated proportion of patients receiving next line of therapy at 180 days vs. acalabrutinib and ibrutinib in 1 L and 2 L.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pinilla-Ibarz et al. (2026) studied this question.

synapsesocial.com/papers/698d6d445be6419ac0d52305 https://doi.org/10.1080/17474086.2026.2628549

View Full Paper

Ask AI

Bookmark

Implication

Real-world treatment switching impacts next line therapy in chronic lymphocytic leukemia and small lymphocytic lymphoma, suggesting differences in efficacy among treatments.

Abstract

Zanubrutinib was associated with lower 90-day switching rates and estimated proportion of patients receiving next line of therapy at 180 days vs. acalabrutinib and ibrutinib in 1 L and 2 L.

Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading